Japan Supreme Court Throws Out Taiko Pharmaceutical Suit Against Izumi Yakuhin
This article was originally published in PharmAsia News
Japan's Supreme Court threw out a lawsuit July 4 brought by Taiko Pharmaceuticals against Izumi Yakuhin Kogyo. Taiko, manufacturer of gastrointestinal drug Seirogan, had asked the court to suspend sales of Izumi Seirogan from Izumi Yakuhin, manufacturer and marketer of Izumi Seirogan. The court said that Seirogan was an accepted name, and that it was easy to distinguish Taiko's product from Izumi's product. (Click here for more - Japanese language
You may also be interested in...
Gilead says remdesivir improved mortality and clinical recovery in COVID-19 patients, but the findings come from a retrospective analysis, not a traditional clinical trial.
Agency resuming domestic inspections with the help of a pandemic rating system to identify localities where inspections will be safest for investigators and plant workers. Another safety factor: all inspections will be pre-announced.
Poseida, Nkarta and Inventiva raised $224m, $252m and $107.7m, respectively. Also, Forbion raised €185m ($208m) of a new €250m fund and Blackstone closed the last $1.2bn of its $4.6bn fund for public and private company deals, and Ascendis led recent follow-ons with a $569.2m offering.